Zhai Yan, Meng Fanqiao, Li Jiaojiao, Ma Junlan, Shen Li, Zhang Wei
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China.
Department of Hematology, Army Medical Center of PLA (Daping Hospital), Army Medical University, Chongqing, China.
Heliyon. 2023 Aug 5;9(8):e18947. doi: 10.1016/j.heliyon.2023.e18947. eCollection 2023 Aug.
Myelodysplastic syndromes (MDS) are a group of myeloid malignancies characterized by peripheral blood cytopenia and hematopoietic dysplasia that often progress to acute myeloid leukemia (AML). Increased apoptosis of normal hematopoietic cells and decreased apoptosis of malignant clonal hematopoietic cells in patients with MDS is some of the mechanisms leading to ineffective hematopoietic cells in the bone marrow. S100 calcium-binding protein A6 (S100A6) is upregulated in many malignancies. The overexpression of S100A6 in these malignancies has been associated with proliferation, migration, and invasion phenotypes in cancer cells, and we aimed to investigate the expression of S100A6 in CD34 cells and the relationship between S100A6 expression and apoptosis of CD34 cells in high-risk patients with MDS.
We measured S100A6 mRNA expression in bone marrow (BM) CD34 cells from high-risk patients with MDS using RT-PCR. Next, we examined S100A6 expression in CD34 cells using flow cytometry. We also analyzed the correlation between CD34 cell apoptosis and S100A6 expression in high-risk patients with MDS.
Our data showed increased S100A6 mRNA expression in CD34 cells in patients with MDS (1.05 ± 0.69 vs. 0.17 ± 0.12; P＜0.01). The expression of S100A6 in BM CD34 cells also increased (58.40 ± 13.18 vs. 45.83 ± 15.01). The expression of S100A6 in CD34 cells and apoptosis of CD34 cells were negatively correlated in patients (r = -0.75; P < 0.01).
Collectively, S100A6 may be a potential marker of CD34 cells in high-risk patients with MDS and may participate in the pathological behaviors of CD34 cells, such as evasion of apoptosis. Thus, S100A6 may be a potential target for eliminating minimal residual disease.
骨髓增生异常综合征（MDS）是一组髓系恶性肿瘤，其特征为外周血细胞减少和造血发育异常，常进展为急性髓系白血病（AML）。MDS患者正常造血细胞凋亡增加而恶性克隆造血细胞凋亡减少是导致骨髓造血细胞无效的部分机制。S100钙结合蛋白A6（S100A6）在许多恶性肿瘤中上调。S100A6在这些恶性肿瘤中的过表达与癌细胞的增殖、迁移和侵袭表型相关，我们旨在研究高危MDS患者CD34细胞中S100A6的表达以及S100A6表达与CD34细胞凋亡之间的关系。
我们使用逆转录聚合酶链反应（RT-PCR）检测高危MDS患者骨髓（BM）CD34细胞中S100A6 mRNA的表达。接下来，我们使用流式细胞术检测CD34细胞中S100A6的表达。我们还分析了高危MDS患者CD34细胞凋亡与S100A6表达之间的相关性。
我们的数据显示，MDS患者CD34细胞中S100A6 mRNA表达增加（1.05±0.69对0.17±0.12；P＜0.01）。BM CD34细胞中S100A6的表达也增加（58.40±13.18对45.83±15.01）。患者CD34细胞中S100A6的表达与CD34细胞凋亡呈负相关（r = -0.75；P < 0.01）。
总体而言，S100A6可能是高危MDS患者CD34细胞的潜在标志物，并可能参与CD34细胞的病理行为，如逃避凋亡。因此，S100A6可能是消除微小残留病的潜在靶点。
